Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Safety, Tolerability and Immune Effects of the Nasal Anti-CD3 Monoclonal Antibody Foralumab in Healthy Human Volunteers

NCT06879067 is registered in ClinicalTrials.gov with Tiziana Life Sciences LTD as lead sponsor.

NCT NCT06879067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06879067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Safety, Tolerability and Immune Effects of the Nasal Anti-CD3 Monoclonal Antibody Foralumab in Healthy Human Volunteers
Lead sponsor
Tiziana Life Sciences LTD
Phase
Phase 1
Overall status
Completed
Start date
November 12, 2018
Completion date
November 9, 2020
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

safety, tolerability